Search
argenx SE
ARGXAdd to Watchlist
993.670USD
+142.380+16.73%
Market hours （ET）Quotes delayed by 15 min
62.14BMarket Cap
41.06P/E TTM
More Details of argenx SE Company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
argenx SE Profile
Ticker SymbolARGX
Company nameargenx SE
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Number of employees1599
Security typeDepository Receipt
Fiscal year-endJul 10
AddressLaarderhoogtweg 25
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1101 EB
Phone31763030
Websitehttps://www.argenx.com/
Ticker SymbolARGX
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Company Executives of argenx SE
Name
Name/Position
Position
Shareholding
Change
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head - Quality
Global Head - Quality
--
--
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Luc Truyen
Dr. Luc Truyen
Chief Medical Officer
Chief Medical Officer
--
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Steve Krognes
Mr. Steve Krognes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head - Quality
Global Head - Quality
--
--
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Luc Truyen
Dr. Luc Truyen
Chief Medical Officer
Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of argenx SE?
The top five shareholders of argenx SE are: Mr. James Michael (Jim) Daly
How many institutions hold shares of argenx SE (ARGX)?
As of 2026Q1, 942 institutions hold shares of argenx SE, with a combined market value of approximately 31.47M, accounting for 50.86% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2793210.00.